NUC-3373 in Advanced Solid Tumours

Phase 1 Completed 62 enrolled University of Oxford

Non-randomizedParallel-groupOpen-labelTreatment

Summary

A two-part, phase I open label, dose escalation and expansion study to assess safety, pharmacokinetics and clinical activity of NUC-3373, a nucleotide analogue, in participants with advanced solid tumours.

Timeline

Start: 2016-01
Primary completion: 2020-02-24
Completion: 2021-02-24

Publications

Spiliopoulou P, Kazmi F, Aroldi F, Holmes T, Thompson D, Griffiths L, Qi C, Parkes M, Lord S, Veal GJ, Harrison DJ, Coyle VM, Graham J, Jeffry Evans TR, Blagden SP. A phase I open-label, dose-escalation study of NUC-3373, a targeted thymidylate synthase inhibitor, in patients with advanced cancer (NuTide:301). J Exp Clin Cancer Res. 2024 Apr 2;43(1):100. doi: 10.1186/s13046-024-03010-1.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Fosifloxuridine Nafalbenamide	Other / unclassified	125 mg/m2	Intravenous
Subject	Fosifloxuridine Nafalbenamide	Other / unclassified	250 mg/m2	Intravenous
Subject	Fosifloxuridine Nafalbenamide	Other / unclassified	500 mg/m2	Intravenous
Subject	Fosifloxuridine Nafalbenamide	Other / unclassified	750 mg/m2	Intravenous
Subject	Fosifloxuridine Nafalbenamide	Other / unclassified	1125 mg/m2	Intravenous
Subject	Fosifloxuridine Nafalbenamide	Other / unclassified	1500 mg/m2	Intravenous
Subject	Fosifloxuridine Nafalbenamide	Other / unclassified	1875 mg/m2	Intravenous
Subject	Fosifloxuridine Nafalbenamide	Other / unclassified	2500 mg/m2	Intravenous
Subject	Fosifloxuridine Nafalbenamide	Other / unclassified	3250 mg/m2	Intravenous

NUC-3373 in Advanced Solid Tumours

Summary

Timeline

Publications

Drugs

Indications